Skip to search boxSkip to navigationSkip to main content

Breast-conserving surgery vs. total mastectomy in patients with triple negative breast cancer in early stages: A propensity score analysis

  • ,
  • Bryan Valcarcel(corresponding author)
    ,
  • Zaida Morante
    ,
  • Mecker G. Möller
    ,
  • Sofia Lizandro
    ,
  • Lia P. Rebaza
*Corresponding author for this work
  • ,
  • Universidad Científica del Sur
    ,
  • Instituto Nacional de Enfermedades Neoplásicas
    ,
  • University of Miami Miller School of Medicine
    ,
  • Sociedad Científica de Estudiantes de Medicina de la Universidad Científica del Sur
    ,
  • Hospital Nacional Dos de Mayo
Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 29-35 (7 pages)

Journal (Volume, Issue Number)

Breast Disease (Volume 39, Issue 1)

Publication milestones

  • Published - 2020

Publication status

Published - 2020

ISSN

0888-6008

Publication IDs

  • Scopus: 85079780845
  • PubMed: 31903977

Abstract

BACKGROUND: Breast-conserving surgery (BCS) as an alternative to total mastectomy (TM) in patients with early-stage triple-negative breast cancer (TNBC) is not widely spread. OBJECTIVE: We aimed to compare the overall survival (OS) and disease-free survival (DFS) between both surgical approaches in early-stage TNBC patients at 10 years. METHODS: We conducted a retrospective cohort study in TNBC female patients with stage I-IIa, treated at a single-center during the period of 2000-2014. We estimated and compared the survival rates with the Kaplan Meier and Long-rank test. Propensity scores were calculated with the generalized boosted regression model and were used in the multivariate Cox regression analysis with the covariate adjustment method. RESULTS: We included 288 patients, 111 in the BCS vs. 177 in the TM group. The median follow-up was 102 months. Moreover, the patients in the BCS group had superior OS (85% vs. 81%, p = 0.56) and DFS (83% vs. 80%, p = 0.42) at 10 years. In the multivariate Cox analysis, BCS decreased the mortality risk (HR: 0.79, 95% CI: 0.37-1.67, p = 0.538), and the locoregional or distant recurrence risk (HR: 0.67, 95% CI: 0.32-1.41, p = 0.294), albeit with no statistical significance. CONCLUSION: BCS is a safe alternative to TM in Latin-American patients with early-stage TNBC.

Funding Details

We thank to all the healthcare and administrative personnel of the National Institute of Neoplastic Diseases for supporting us in the development of this manuscript. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
FundersFunding numbers
National Institute of Neoplastic Diseases
-

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Captures
36
Citations
9

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well